Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2025-04-01 Transaction in Own Shar…
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Diasorin S.p.A. - Allegato 3F
Transaction in Own Shares Classification · 98% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Disclosure Form for Transactions in the Issuer's Securities) from DIASORIN S.P.A. Section 2 details a specific transaction involving the sale ('V' for Vendita) of 10,000 shares on 17/03/2025. The notes explicitly state this is a sale of own shares following the exercise of stock options. This type of filing, reporting transactions by the company in its own shares (treasury shares or share buybacks/sales), directly corresponds to the definition of 'Transaction in Own Shares'.
2025-04-01 Italian
Notice to shareholders - Offer in option and pre-emption
Capital/Financing Update Classification · 98% confidence The document is titled "NOTICE TO SHAREHOLDERS OF DIASORIN S.P.A." and specifically announces a "NOTICE OF OFFER IN OPTION AND PRE-EMPTION PURSUANT TO ARTICLE 2437-QUATER, PARAGRAPHS 1 AND 2, OF THE ITALIAN CIVIL CODE". This notice details the process for offering shares that were subject to a withdrawal right following a shareholder meeting resolution regarding enhanced voting rights. The content focuses on the mechanics of an offer (Option Rights, pre-emptive rights, offer price, record date, offer period) related to capital structure adjustments stemming from shareholder actions. This clearly falls under financing activities or capital structure changes, making 'Capital/Financing Update' (CAP) the most appropriate classification, as it deals directly with the issuance/re-offering of shares following a capital event (withdrawal rights exercise). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2025-04-01 English
Avviso agli azionisti - Offerta in opzione e prelazione
Share Issue/Capital Change Classification · 95% confidence The document is an 'AVVISO AGLI AZIONISTI DI DIASORIN S.P.A.' (Notice to Shareholders of Diasorin S.p.A.) concerning an 'OFFERTA IN OPZIONE E PRELAZIONE' (Option and Pre-emption Offer) for shares subject to withdrawal rights following a shareholder resolution regarding a boosted voting system. It details the mechanics, pricing (€103.05 per share), record date, and subscription period (March 31, 2025, to April 30, 2025). This is a formal corporate action related to capital structure/shareholder rights following a corporate event (the AGM resolution mentioned). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). It specifically details the terms of an offer related to capital changes resulting from shareholder action, fitting best under Capital/Financing Update (CAP) or potentially a specialized filing related to share structure, but given the context of offering shares resulting from a capital/governance change, CAP is the most appropriate fit among the provided options, as it directly concerns the structure and offering of shares following a corporate decision. It is a detailed offer document, not just an announcement of a report (RPA).
2025-04-01 Italian
Adoption of the enhancement of the increased voting mechanism: withdrawal right exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement from Diasorin S.p.A. dated March 31, 2025, regarding the 'Adoption of the enhancement of the increased voting rights mechanism: withdrawal right exercised by 1.69% of the share capital' and the start of the 'Statutory option and pre-emption offer period'. This announcement details the results of a shareholder vote consequence (withdrawal rights exercised) and initiates a subsequent capital/share transaction process (offering withdrawn shares back to existing shareholders via option and pre-emption rights). This directly relates to changes in the company's capital structure and shareholder rights following a corporate action. While it involves shareholder actions, it is fundamentally about the mechanics of share reallocation and capital structure adjustment following a governance change, making 'Capital/Financing Update' (CAP) the most appropriate fit, as it describes the process initiated due to the exercise of withdrawal rights which impacts the share base and subsequent offering mechanism. It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). It is a specific announcement detailing the financial and procedural consequences of a shareholder vote outcome related to capital structure.
2025-03-31 English
Adozione del voto maggiorato potenziato: esercizio del diritto di recesso da parte dell'1,69% del capitale sociale. Al via dal 31 marzo 2025 l'offerta in opzione e prelazione
Share Issue/Capital Change Classification · 99% confidence The document is an official communication from Diasorin S.p.A. dated March 31, 2025, regarding the outcome of the exercise of the right of withdrawal (recesso) following the adoption of enhanced majority voting rights. It details the number of shares withdrawn (1.69% of capital), the liquidation value (€103.05 per share), and the status of the contingent resolution conditions related to the total cash outlay. Crucially, it announces the start of the option and pre-emption offer period for these withdrawn shares, scheduled from March 31, 2025, to April 30, 2025. This announcement concerns a significant corporate action related to capital structure and shareholder rights following a shareholder meeting decision, which directly relates to financing activities or capital structure changes. While it touches upon shareholder rights (like DVA), the core subject is the financial mechanism triggered by the withdrawal process and the subsequent offer to repurchase shares, which aligns best with Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). It is a detailed announcement of a capital event.
2025-03-31 Italian
Report on the remuneration policy for the year 2025 and remuneration paid in the year 2024
Remuneration Information Classification · 100% confidence The document is explicitly titled "Report on the Remuneration Policy for the year 2025 and remuneration paid in the year 2024". It references Italian regulatory articles (Article 123-ter of the Consolidated Finance Act and Article 84-quater of the Issuers' Regulation) which govern the disclosure of executive and director compensation. The table of contents details sections on 'Remuneration of the Members of the Board of Directors', 'Remuneration Of The CEO/General Manager', and 'Implementation of the 2024 Remuneration Policy'. This content directly aligns with the definition of a Remuneration Information document, which corresponds to the code DEF 14A (Proxy Solicitation & Information Statement often covers this, but DEF 14A specifically relates to executive compensation disclosure in US context, and the provided definition for DEF 14A is 'Report detailing compensation for top executives and directors'). Given the specific focus on remuneration policy and paid remuneration, DEF 14A is the most appropriate classification among the provided options, even though the document is Italian, as it covers the required disclosure type.
2025-03-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.